Ye Fang

Dr. Ye Fang

Biochemical Technologies, Science and Technology Division, Corning Incorporated, Sullivan Park, Corning, NY 14870, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2006 in Biophysical Journal
Verified
Journal Article
Closed access
YFYe Fang
Ye Fang
AFAnn M. Ferrie
Ann M. Ferrie
NFNorman H. Fontaine
Norman H. Fontaine
JMJohn Mauro
John Mauro
JBJitendra Balakrishnan
Jitendra Balakrishnan

12 February 2016 in Science
Verified
Journal Article
Closed access
PDF file
JFJarrod B. French
Jarrod B. French
SJSara A. Jones
Sara A. Jones
HDHuayun Deng
Huayun Deng
APAnthony M. Pedley
Anthony M. Pedley
DKDoory Kim
Doory Kim
SBStephen Benkovic
Stephen Benkovic
Spatial control of cellular enzymes: Purine is a building block of DNA and also a component of ATP that is used as an energy source in the cell. Enzymes involved in purine biosynthesis organize into dynamic bodies called purinosomes. French et al. found that purinosomes colocalize with mitochondria, organelles that generate ATP (see the Perspective by Ma and Jones). Dysregulation of mitochondria caused an increase in the number of purinosomes. This suggests a synergy, with the purinosomes supplying the purine required for ATP production and in turn using ATP in the biosynthetic pathway. A master regulator of cellular metabolism, mTOR, appears to mediate the association of purinosomes and mitochondria. This could make purine and ATP synthesis responsive to changes in the metabolic needs of the cell. Science , this issue p. 733 ; see also p. 670

1 October 2006 in ASSAY and Drug Development Technologies
Verified
Journal Article
Closed access
YFYe Fang
Ye Fang
Once viewed solely as a tool for low throughput and kinetic analysis of biomolecular interactions, optical biosensors are gaining widespread uses in drug discovery because of recent advances in instrumentation and experimental design. These advances have expanded the capabilities of optical biosensors to meet the needs at many points in the drug discovery process. Concurrent shifts in drug discovery paradigms have seen the growing use of whole cell systems for drug screens, thus creating both a need in drug discovery and a solution in optical biosensors. This article reviews important advances in optical biosensor instrumentation, and highlights the potential of optical biosensors for drug discovery with an emphasis on whole cell sensing in both high throughput and high content fashions.

26 February 2002 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
YFYe Fang
Ye Fang
AFAnthony G. Frutos
Anthony G. Frutos
JLJoydeep Lahiri
Joydeep Lahiri

6 August 2005 in Analytical Chemistry
Verified
Journal Article
Closed access
YFYe Fang
Ye Fang
AFAnn M. Ferrie
Ann M. Ferrie
NFNorman H. Fontaine
Norman H. Fontaine
PYPo Ki Yuen
Po Ki Yuen

4 August 2012 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
YFYe Fang
Ye Fang
The study of drug-target interactions is essential for the understanding of biological processes and for the efforts to develop new therapeutic molecules. Increased ligand-binding assays have coincided with the advances in reagents, detection and instrumentation technologies, the expansion in therapeutic targets of interest, and the increasingly recognized importance of biochemical aspects of drug-target interactions in determining the clinical performance of drug molecules. Nowadays, ligand-binding assays can determine every aspect of many drug-target interactions. Given that ligand-target interactions are very diverse, the author has decided to focus on the binding of small molecules to protein targets. This article first reviews the key biochemical aspects of drug-target interactions, and then discusses the detection principles of various ligand-binding techniques in the context of their primary applications for drug discovery and development. Equilibrium-binding affinity should not be used as a solo indicator for the in vivo pharmacology of drugs. The clinical relevance of drug-binding kinetics demands high throughput kinetics early in drug discovery. The dependence of ligand binding and function on the conformation of targets necessitates solution-based and whole cell-based ligand-binding assays. The increasing need to examine ligand binding at the proteome level, driven by the clinical importance of the polypharmacology of ligands, has started to make the structure-based in silico binding screen an indispensable technique for drug discovery and development. Integration of different ligand-binding assays is important to improve the efficiency of the drug discovery and development process.